Avoid common mistakes on your manuscript.
Correction to: Clinical and Translational Oncology https://doi.org/10.1007/s12094-023-03203-8
In the sentence beginning “Therefore, tucatinib–lapatinib–capecitabine…” in this article, the text “tucatinib–lapatinib–capecitabine” should have read “tucatinib–trastuzumab–capecitabine” and the correct sentence should read as follows:
Therefore, tucatinib–trastuzumab–capecitabine may be a good option for patients treated with previous T-DM1 and/or T-Dxd [II, B].
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Garcia-Saenz, J.A., Blancas, I., Echavarria, I. et al. Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol 25, 2759 (2023). https://doi.org/10.1007/s12094-023-03229-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-023-03229-y